Contributions
Abstract: P821
Type: Poster
Abstract Category: Therapy - symptomatic - 34 Quality of life
Background and objective: Validated quality-of-life (QOL) tools are not available for Arabic-speaking MS patients. SF36 and MUSIQOL have been validated for other languages. The objective of this study was to prospectively assess and correlate MUSIQOL with disease activity and progression among Arabic-speaking MS patients treated with INF-β 1a sc injection New Formulation over 12 months.
Methods: The subjects comprised a prospective multinational, multicenter cohort study of Arabic-speaking MS patients treated with RNF for at least 6 months prior to entering the study. Their clinical parameters and QOL were assessed at baseline, and by follow-up after 6 months and 12 months. Changes in MUSIQOL total and subdomain scores were compared by using the Paired T test. QOL changes from baseline and important parameters in QOL were correlated by using Pearson and Point Biserial methods.
Results: 439 subjects from four Arabic-speaking countries were included. Their average age was 32.44(±0.34) years, 71.5% were female, and 63.1% were educated to university level or above. The subjects had an average MS duration of 4.13(±0.12) years, an average age at first attack of 27.35(±0.26) years, and baseline EDSS of 2.05±0.04. Overall QOL measured using SF36 remained generally unchanged over time (P=0.215). However, QOL change overtime measured by using MUSIQOL was statistically significant (P=0.00015). Several aspects of subjects' QOL, including daily living activities, physical wellbeing, symptoms, and coping improved. Sentimental & sexual life decreased overtime (p=0.0072).
Conclusion: The study suggests that the use of MUSIQOL among Arabic-speaking MS patients is a valid tool, and may capture changes in several aspects of their clinical status over 12 months. Periodic assessment of QOL is recommended for management of MS patients.
INF-β 1a sc = Interferon beta 1 a subcutaneous
Disclosure:
Dr.Mohamed Al Jumah: nothing to disclose.
Dr.Mohamed Hussein: nothing to disclose.
Dr.Edward Cuplar: nothing to disclose.
Dr.Raed Al Roughani: nothing to disclose.
Dr.Saeed Bohlegah: nothing to disclose.
Dr.Abdulkader Daif: nothing to disclose.
Dr.Abdulaziz Zamzami: nothing to disclose.
Dr.Moussa Mujalli: nothing to disclose.
Dr.Talal Al Harbi: nothing to disclose.
Dr.Mohamed El Tamawy: nothing to disclose.
Dr.Samia Ashour: nothing to disclose.
Dr.Samir BELAL: nothing to disclose.
Dr.Chokri MHIRI: nothing to disclose.
Dr Ridha MRISSA: nothing to disclose.
Dr Riadh GOUIDER: nothing to disclose.
Dr.Ayah Jawhary: nothing to disclose.
Dr.Suleiman Kojan: nothing to disclose.
Abstract: P821
Type: Poster
Abstract Category: Therapy - symptomatic - 34 Quality of life
Background and objective: Validated quality-of-life (QOL) tools are not available for Arabic-speaking MS patients. SF36 and MUSIQOL have been validated for other languages. The objective of this study was to prospectively assess and correlate MUSIQOL with disease activity and progression among Arabic-speaking MS patients treated with INF-β 1a sc injection New Formulation over 12 months.
Methods: The subjects comprised a prospective multinational, multicenter cohort study of Arabic-speaking MS patients treated with RNF for at least 6 months prior to entering the study. Their clinical parameters and QOL were assessed at baseline, and by follow-up after 6 months and 12 months. Changes in MUSIQOL total and subdomain scores were compared by using the Paired T test. QOL changes from baseline and important parameters in QOL were correlated by using Pearson and Point Biserial methods.
Results: 439 subjects from four Arabic-speaking countries were included. Their average age was 32.44(±0.34) years, 71.5% were female, and 63.1% were educated to university level or above. The subjects had an average MS duration of 4.13(±0.12) years, an average age at first attack of 27.35(±0.26) years, and baseline EDSS of 2.05±0.04. Overall QOL measured using SF36 remained generally unchanged over time (P=0.215). However, QOL change overtime measured by using MUSIQOL was statistically significant (P=0.00015). Several aspects of subjects' QOL, including daily living activities, physical wellbeing, symptoms, and coping improved. Sentimental & sexual life decreased overtime (p=0.0072).
Conclusion: The study suggests that the use of MUSIQOL among Arabic-speaking MS patients is a valid tool, and may capture changes in several aspects of their clinical status over 12 months. Periodic assessment of QOL is recommended for management of MS patients.
INF-β 1a sc = Interferon beta 1 a subcutaneous
Disclosure:
Dr.Mohamed Al Jumah: nothing to disclose.
Dr.Mohamed Hussein: nothing to disclose.
Dr.Edward Cuplar: nothing to disclose.
Dr.Raed Al Roughani: nothing to disclose.
Dr.Saeed Bohlegah: nothing to disclose.
Dr.Abdulkader Daif: nothing to disclose.
Dr.Abdulaziz Zamzami: nothing to disclose.
Dr.Moussa Mujalli: nothing to disclose.
Dr.Talal Al Harbi: nothing to disclose.
Dr.Mohamed El Tamawy: nothing to disclose.
Dr.Samia Ashour: nothing to disclose.
Dr.Samir BELAL: nothing to disclose.
Dr.Chokri MHIRI: nothing to disclose.
Dr Ridha MRISSA: nothing to disclose.
Dr Riadh GOUIDER: nothing to disclose.
Dr.Ayah Jawhary: nothing to disclose.
Dr.Suleiman Kojan: nothing to disclose.